$ News

Quetzal Therapeutics Debuts with Expert Leadership, High-Impact Pipeline and $50 Million of Committed Capital

Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration

'We are back' Greek shipyards say after decades of pain

Recursion: CDK7 Inhibitor Differentiation Is Initially Paying Off

Kia starts series production of Syros in India

South Africa’s Westfalia Fruit acquires Belgian avocado products maker Syros

Kia launches Syros compact SUV in India

Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright

Syros stock craters after lead cancer therapy flops in Phase III trial

Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression

Syros Pharmaceuticals Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$1.43 loss in 3Q 2023)

Syros Pharmaceuticals Inc (SYRS) Q3 2024 Earnings Call Highlights: Strategic Focus on ...

Syros Pharmaceuticals, Inc (SYRS) Q3 2024 Earnings Call Transcript

Syros Pharmaceuticals Reports Q3 2024 Financial Results

Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update

Syros Pharmaceuticals: Promising Prospects with Strong Cash Position and Advancing Phase 3 Trial in HR-MDS

Syros Pharmaceuticals: Promising Breakthrough with Tamibarotene in High-Risk MDS

Syros Pharmaceuticals reports Q3 EPS (16c), consensus (72c)

Syros Pharmaceuticals GAAP EPS of -$0.16 beats by $0.52

Syros Pharmaceuticals Q3 2024 Earnings Preview